Rrd Logo (Rrd Group Logo)
Signifor Injection
Product Images NDC 55292-132
19 FDA label images from Recordati Rare Diseases, Inc. · Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 19 technical images submitted to the FDA as part of the official labeling for Signifor (NDC 55292-132). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Recordati Rare Diseases, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Signifor-0.9mg-ml (Signifor 0.3mg mL)
Packaging label for Signifor (pasireotide) Injection, 0.3 mg/mL, a subcutaneous injection. The flat layout shows the carton design with the product name, strength, dosage form, route, and labeler Recordati Rare Diseases, Inc. clearly visible along with standard regulatory text and a barcode.*
Signifor-0.6mg-ml (Signifor 0.6mg mL)
Packaging label for Signifor (pasireotide) Injection 0.6 mg/mL, a subcutaneous injection. The label features the proprietary name Signifor and the generic name pasireotide. The label indicates the strength as 0.6 mg/mL and includes usage instructions for subcutaneous administration. The labeler is Recordati Rare Diseases, Inc. The label design includes red accents and dosage information on multiple panels of a carton.*
Signifor-0.9mg-ml (Signifor 0.9mg mL)
Packaging label for Signifor (pasireotide) injection, 0.9 mg/mL strength, for subcutaneous injection. The label displays the proprietary and generic names, strength, injectable form, and a package count of 10 single-dose 1 mL ampules. The labeler is Recordati Rare Diseases, Inc. The design includes barcodes and regulatory text.*
The Structural Formula Of Pasireotide Diaspartate. (Signifor 01)
Chemical structure of pasireotide, the active ingredient in Signifor injection. The diagram shows the molecular arrangement of atoms and bonds characteristic of this peptide-based compound.*
Figure 1 – Mean (± Se) Urinary Free Cortisol (nmol/24h) At Time Points Up To Month 6 By Randomized Dose Group (Signifor 02)
A line graph comparing biochemical measurement levels (in nmol/24h) over 6 months for Signifor injection at 0.9 mg and 0.6 mg dosages. The y-axis shows nmol/24h values from 0 to 1000, while the x-axis shows months from 0 to 6. Both dosage groups show a sharp decline initially and stabilize near the normal range.*
Figure A And Figure B (Signifor 03)
An instructional diagram displaying components of the Signifor (pasireotide) injection. Figure A shows an ampule with labeled parts: a colored dot, breaking point below the dot, and liquid inside labeled as Signifor injection. Figure B illustrates the syringe parts, including cover, plunger, and syringe body, alongside two needle types: long needle and short needle.*
Figure C (Signifor 04)
An instructional diagram showing two ampoules of Signifor (pasireotide) injection. One ampoule highlights where the expiration date and lot number are located on the label, while the other indicates the injection dose area, emphasizing the product name and Rx only designation.*
Figure D (Signifor 05)
An instructional line drawing showing a pair of hands removing a cap from a small vial or injection device. One hand holds the vial, while the other grasps the cap, illustrating preparation steps for administering an injection.*
Figure E (Signifor 06)
An instructional illustration showing hands demonstrating how to snap off a glass ampule at the breaking point to access the injectable medication inside.*
Figure F (Signifor 07)
An instructional illustration showing a person holding a vial with one hand and a syringe with the other, preparing to insert a long or short needle into the vial. The image demonstrates correct needle selection for drawing medication.*
Figure G (Signifor 08)
An instructional illustration showing a hand removing the needle cover from a syringe. The image emphasizes the step of handling the needle cover prior to injection.*
Figure H (Signifor 09)
An instructional diagram showing a hand holding a syringe being withdrawn from a vial. An upward arrow indicates the direction to pull the syringe plunger to draw medication from the vial, consistent with preparation for injection.*
Figure I (Signifor 0a)
An instructional line drawing showing hands preparing a syringe for injection by tapping the syringe to remove air bubbles. The illustration is related to the preparation of Injection products, such as Signifor (pasireotide) subcutaneous injection.*
Figure J (Signifor 0b)
An instructional illustration showing a hand holding a syringe in preparation for use. The thumb is positioned to pull back the plunger, indicated by a black upward arrow, suggesting the step of drawing medication into the syringe.*
Figure K (Signifor 0c)
An instructional illustration showing hands cleaning the forearm with an alcohol wipe, likely preparing the skin for a subcutaneous injection site. The image focuses on the proper area and technique for skin preparation before an injection.*
Figure L (Signifor 0d)
An instructional illustration showing two hands performing a subcutaneous injection. One hand is holding the skin pinched while the other hand inserts a syringe needle at an angle, indicating the proper technique for subcutaneous administration.*
Figure M (Signifor 0e)
An instructional illustration showing a hand holding a syringe injecting a subcutaneous injection into the forearm of another hand. The image demonstrates the procedure for administering a subcutaneous injection.*
Figure N (Signifor 0f)
An instructional line drawing showing a hand holding a syringe or injection pen aimed for subcutaneous injection into an arm or leg. The image visually depicts the correct injection technique for a subcutaneous route.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
